GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » Cash Conversion Cycle

Seagen (Seagen) Cash Conversion Cycle : 273.05 (As of Sep. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Seagen Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Seagen's Days Sales Outstanding for the three months ended in Sep. 2023 was 85.64.
Seagen's Days Inventory for the three months ended in Sep. 2023 was 281.07.
Seagen's Days Payable for the three months ended in Sep. 2023 was 93.66.
Therefore, Seagen's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2023 was 273.05.


Seagen Cash Conversion Cycle Historical Data

The historical data trend for Seagen's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Cash Conversion Cycle Chart

Seagen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 150.53 253.41 107.17 155.37 218.71

Seagen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 256.09 270.86 314.36 260.62 273.05

Competitive Comparison of Seagen's Cash Conversion Cycle

For the Biotechnology subindustry, Seagen's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seagen's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seagen's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Seagen's Cash Conversion Cycle falls into.



Seagen Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Seagen's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=82.88+279.44-143.61
=218.71

Seagen's Cash Conversion Cycle for the quarter that ended in Sep. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=85.64+281.07-93.66
=273.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Seagen  (NAS:SGEN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Seagen Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Seagen's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Seagen (Seagen) Business Description

Traded in Other Exchanges
N/A
Address
21823 - 30th Drive South East, Bothell, WA, USA, 98021
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Executives
David R Epstein director, officer: Chief Executive Officer INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes officer: See Remarks C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp officer: EVP, Commercial 21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu officer: GC & EVP, Legal Affairs 21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson officer: Chief Financial Officer
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain director 21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014

Seagen (Seagen) Headlines

From GuruFocus

This Insider Just Sold Shares of Seagen Inc

By GuruFocus Research GuruFocus Editor 05-19-2023

Seagen to Present at the Cowen 43rd Annual Health Care Conference

By Business Wire Business Wire 02-27-2023